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ABSTRACT 
 
The  aim  of  this  study  is  to investigate  the  need  for  anti-tetanus  immunisation  in  Nigerians  living  with  HIV/AIDS  by 
quantifying antibody to tetanus organism in them. Both symptomatic and asymptomatic consenting Nigerians positive for 
HIV infection and aged 15 years and above were included in the study. Apparently healthy age- and sex-matched 
subjects were enrolled as controls. Immunisation history was recorded in all participants. The PCV, WBC, platelet and 
CD4+ cell counts were done on automated counter. Serum levels of antibody to tetanus were quantitated using standard 
ELISA method. There was no significant difference (t = 0.138, p = 0.89) in the mean serum levels of antibody to tetanus 
in patients with HIV/AIDS (0.5 ± 0.86 IU/mL) when compared with the controls (0.46 ± 0.52 IU/mL). About 85.7% (36/42) 
of patients with HIV/AIDS had protective tetanus antibody and only six (14.3%) had non-protective antibody levels. In 
patients with CD4+ T lymphocytes of < 200 cells/µL, the mean anti-tetanus antibody was 0.50 ± 0.98 IU/mL, while in 
those  with  CD4+  T  lymphocytes  of  >  200  cells/µL,  it  was  0.53  ±  0.53  IU/mL.  The  difference  was  not  statistically 
significant (t = 0.1, p = 0.918). The majority of our patients presented in advanced stage with 69% of them having CD4+ 
T lymphocytes < 200 cell/µL. This study found a significant number of Nigerians with HIV/AIDS having protective levels 
of antibody to tetanus in their sera. We therefore suggest continue efforts at improving on the National Programme on 
Immunisation, as immunisation in patients with HIV infection may not yield adequate responses and may be fraught with 
the risk of increase in viral replication. 
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INTRODUCTION 
 
Tetanus  is  serious  but  preventable  disease  that 
affects  the  neuro-muscular  system  of  the  body.  The 
disease  is  caused  by  the  toxin  of  Clostridium  tetani,  a 
bacterium found in the soil, stool and anything lying on the 
ground.  Among  HIV-infected  individuals,  skin 
lesions/diseases are known to cause significant morbidity, 
and could either as a result of the disease (Mohammad et 
al., 2003; Resneck et al., 2004) or due to adverse drug 
reactions (Namayanja et al., 2005; Manosuthi et al., 2006;  
Forna et al., 2007). In view of the possible contamination 
of the skin lesions from the environment or autoinfection 
from diarrheal stool, the need for vaccination (Kurtzhals et 
al.,  1992)  against  this  disease  has  been  suggested  to 
avert  the  serious  disease  in  the  already 
immunocompromised individuals. The aim of this study is 
therefore  to  investigate  the  level  of  antibody  to  tetanus 
toxin in Nigerians living with HIV/AIDS, a study that has 
not been done before. 
 
MATERIALS AND METHODS 
 
Confirmed HIV/AIDS patients seen between July and 
 
 
December  2006  at  the  Communicable  Diseases  and 
Haematology  clinics  of  the  Obafemi  Awolowo  University 
Teaching Hospitals Complex (OAUTHC), Ile-Ife, Nigeria, 
were  consecutively  recruited  into  the  study.  Ethical 
clearance was obtained from the hospital’s Research and 
Ethics  Committee.  Written  consent  was  also  obtained 
from all patients after been assured of confidentiality. Both 
symptomatic  and  asymptomatic  consenting  Nigerians 
positive for HIV infection and aged 15 years and above 
were included in the study. Apparently healthy age- and 
sex-matched subjects were enrolled as controls. Age and 
gender  of subjects and  controls  were  also  documented. 
History  of  immunisation  was  also  documented  in  both 
patients and controls. 
Blood samples were taken, in appropriate bottles, for 
blood counts (packed cell volume, white blood cells and 
differentials,  platelets),  CD4+  cell  count  and  serum 
tetanus antibody level.  Haematological  parameters  were 
estimated within 6 h of sample collection, while sample for 
tetanus antibody level were stored at temperature of ‒20 
° C  and  estimated  in  batches.  The  packed  cell  volume, 
white cells and platelet counts were done on automated 
counter (ADVIA-60 Bayer Corporation, New York, United 
States of America), while CD4+ cell count were done on 
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automated counter (Partec Cyflow, GmbH, Otto-Hahn-Str. 
32;  D-48161  Munster,  Germany).    Serum  levels  of 
antibody  to  tetanus  were  quantitated  using  Tetanus 
Toxoid IgG Elisa Kit (Demeditec Diagnostic GmbH * Lise-
Meitner-Straβe 2 * D-24145 Kiel, Germany) following the 
manufacturer’s  instructions  (Bio-Rad,  2005).  Serum 
samples  for  IgG  antibody  to  tetanus  quantitation  were 
retrieved from the ‒20 ° C freezer, allowed to thaw to room 
temperature and analysed in one batch. After passing the 
samples  and  standards  through  ELISA  reactions,  their 
concentrations (and optical densities) were then read with 
a  microplate  reader  (Model  550;  Bio-Rad  Laboratories, 
Hercules,  USA)  at  450  nm,  according  to  the 
manufacturer’s  instructions  (Bio-Rad,  2005).  Tetanus 
antibody was expressed in International Units per millilitre 
(IU/mL)  and  results  interpreted  according  to 
manufacturer’s recommendations which state that value of 
antibody  less  than  0.1  IU/mL  requires  immunization 
(Demeditec Diagnostics) 
Data  analysis:  Data  are  presented  as  means  and 
standard  deviations  (means  ±  SD).  Student’s  t-test  was 
used to test the significance of differences between mean 
values with statistical significance set at p value less than 
0.05.    Data  were  analysed  using  SPSS  11  (SPSS  Inc, 
Chicago, USA, SPSS Inc 1989-2001) statistical software. 
 
RESULTS 
 
Characteristics of the study population: Forty-two patients 
living  with  HIV/AIDS and  10 apparently healthy  persons 
were investigated. Of the patients living with HIV/AIDS, 14 
were males while the rest 28 were females with a male to 
female ratio of 1:2; while more females (six females, four 
males) were also investigated in the control arm, with a 
male to female ratio of 1:1.5.The mean age in the patient 
group was 36.69 ± 9.29 years and in control group was 
43.00  ±  16.24  years  (t  =  ‒1.648,  p  =  0.106)  with  no 
significant difference. The majority of participants admitted 
to have had immunisation during childhood (Table 1).   
Haematological  characteristics:  The  mean  (±  SD) 
haematocrit in the HIV/AIDS subjects (32.40 ± 16.24%), 
as  expected,  was  significantly  lower  compared  with  the 
controls (39.40 ± 4.58%) (t = ‒3.64, p = 0.001). However, 
the  mean  WBC  though  also  higher  in  the  controls 
(4289.29 ± 2016.62/cmm and 5380.00 ± 1250.60/cmm for 
HIV/AIDS  patients  and  controls,  respectively),  was  not 
significant  (t  =  ‒1.63,  p  =  0.11).  Similarly,  the  mean 
platelet was expectedly higher in the controls (191857.14 
±  9330.92/cmm  and  225200.00  ±  58537.36/cmm  for 
HIV/AIDS  patients  and  controls,  respectively),  was  not 
significant (t = ‒1.076, p = 0.29). 
Seroprevalence  of  tetanus  antibody:  There  was  no 
significant  difference  (t  =  0.138,  p  =  0.89)  in  the  mean 
tetanus  antibody  levels  in  patients  living  with  HIV/AIDS 
(0.5  ±  0.86  IU/mL)  compared  with  that  of  the  controls 
(0.46 ± 0.52 IU/mL) (Table 1). By internationally accepted 
serum level of anti-tetanus antibody (Bonetti et al., 2004), 
85.7%  (36/42)  of  patients  living  with  HIV/AIDS  had 
protective  levels  of  antibody  to  tetanus,  with  only  6 
(14.3%)  of  the  42  having  non-protective  antibody  to 
tetanus in their sera.  
CD4+  cell  count  in  subjects:  The  mean  CD4+  cell 
count  in  patients  (166.10  ±  102.95  cells/µL)  was 
significantly  lower  (t  =  12.22,  p  =  0.00)  that  what  was 
found in the controls (708.00 ± 122.28) (Table 1). Twenty-
nine (29/42 or 69%) of the patients had CD4+ cell count of 
less than 200 cells /µL, while the rest 13 (31%) had CD4+ 
T  lymphocytes  of  200  cells  or  above  showing  that  the 
majority of how patients presented in advanced stage of 
the disease. 
Tetanus  antibody  according  to  CD4+  T  lymphocyte 
counts: Mean antibody levels to tetanus in patients living 
with HIV/AIDS were not significantly different based on the 
circulating  CD4+  T  lymphocytes  counts  (Table  1).  In 
patients with CD4+ T lymphocytes of < 200 cells/µL, the 
mean anti-tetanus antibody ± SD was 0.50 ± 0.98 IU/mL, 
while in those with CD4+ T lymphocytes of > 200 cells/µL, 
it  was  0.533  ±  0.531  IU/mL  (t  =  0.1,  p  =  0.918).  In 
regression  analysis,  there  were  also  no  significant 
differences  in  subjects’  age  and  serum  level  of  tetanus 
antibody  (t  =  ‒1.15,  p  =  0.25)  or  subjects’  number  of 
circulating CD4+ cells count and serum level of tetanus 
antibody (t = ‒0.32, p = 0.75). 
 
DISCUSSION  
 
This preliminary study on the quantification of serum level 
of antibody to tetanus organism was done to assess the 
need  for  prophylactic  vaccination  of  people  living  with 
HIV/AIDS as they are likely to present with more severe 
outcome than the seronegative individuals.  The tetanus 
organism is found in the soil, stool and anything lying on 
the  ground  and  as  such  could  easily  contaminate  open 
wounds,  such  as  dermatological  lesions  (Garbe  et  al., 
1994; Munoz-Perez et al., 1998) that are not uncommon 
occurrence in HIV/AIDS patients either resulting from the 
disease  or  secondary  to  antiretroviral  (ARV)  or  other 
medications  in  the  management  of  the  patient.  In  this 
study,  we  do  not  found  any  significant  difference in  the 
serum  levels of  antibody  to  tetanus  in  Nigerian  patients 
living with HIV/AIDS and the seronegative controls. This is 
an  important  finding  in  HIV  infection  since  the  infection 
alters  immune  functions,  immunisation  of  HIV  infected 
persons may not confer the same protection as may be 
possible  in  immunocompetent  persons.  Also, 
immunisation of HIV-infected persons can enhance viral 
replication  as  a  result  of  immune  stimulation  (Castello-
Branco  and  Ortigao-de-Sampaio,  1998)  leading  to  a 
rapidly  progressive  disease.  Although  studies  have  also 
shown that HIV-infected children are able to mount both 
cellular  and  humoral  immune  responses  to  commonly 
administered  vaccines  in  the  first  two  years  of  life 
(Borkowsky et al., 1992), antibody level tend to be lower 
and  to  decrease  more  rapidly  over  time  compared  to 
immunocompetent  individuals  (Ryder  et  al.,  1993).  The 
implication  of  this  is  that  attempt  at  prophylactic 
vaccination of our patients (if the anti-tetanus antibody are 
non-protective)  is  that  the  desired  effect  may  not  be 
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Table 1: Immuno-haematological and demographic parameters of Nigerians living with HIV/AIDS 
  HIV/AIDS  Control  t-value  p-value 
Age (in years)  36.69 ± 9.29  43.00 ± 16.24  -1.18  0.11 
PCV (%)  32.40 ± 5.64  39.40 ± 4.58  -3.64  0.001 
WBC (/cmm)  4289.29 ± 2016.62  5380.00 ± 1250.60  -1.63  0.109 
Platelet (/cmm)  191857.14 ± 93301.92  225200.00 ± 58537.36  -1.08  0.87 
Tab (IU/mL)  0.50 ± 0.86  0.46 ± 0.65  0.14  0.89 
CD4+ (/µL)  166.10 ± 102.94  708.00 ± 122.28  12.22  0.00 
*CD4+ < 200  0.50 ± 0.98       
*CD4+ > 200  0.49 ± 0.53    0.04  0.97 
 
Tab: serum tetanus antibody; IU/mL = international unit per millilitre; *CD4+: serum anti-tetanus antibody with CD4+ cells of < 200 and 
CD4+ cells of > 200 cells/µL; PCV: packed cell volume (in percentage); WBC: white blood cell (per cm
3) 
 
achieved.  Although  the  CDC  approved  the  use  of 
inactivated  vaccines  (such  as  diphtheria,  pertussis  and 
tetanus  in  HIV  patients  (Centre  for  Diseases  Control, 
1988), studies have shown that even tetanus toxoid can 
cause increase in viremia and proviral burden in patients 
with HIV infection when given the Toxoid (Stanley et al., 
1996) 
The  majority  of  our  patients  had  advanced  disease 
with  69%  of  them  having  CD4+  T  lymphocytes  <  200 
cells/µL.  This  is  also  reflected  in  their  reduced 
haematocrit, WBC and platelet counts. This is probably a 
disadvantage  in  achieving  good  results  if  they  are  to 
receive  immunisation  as  studies  have  shown  that  in 
patients with advanced HIV infection had fewer antibody 
production  responses  than  patients  with  asymptomatic 
infection  (Janoff  et  al.,  1988).  It  has  also  been 
documented  that  even  among  patients  that  are 
asymptomatic,  responses  of  patients  with  CD4+  T 
lymphocyte count of > 500 cells/µL were similar to HIV-
negative  individuals,  whereas  the  responses  of  patients 
with  CD4+  T  lymphocyte  count  of  <  500  cells/µL  were 
significantly  lower  (Rodriguez-Barradas  et  al.,  1992).  A 
similar  study  also  showed  that  antibody  production  to 
inactivated  polio  vaccine  is  better  with  CD4+  T 
lymphocytes  >  200  cells/µL  (Vardinon  et  al.,  1990). 
Therefore, the level of CD4+ T lymphocytes in HIV/AIDS 
patient could be an important factor in patient’s response 
to  vaccination.  The  role  of  CD4+  T  lymphocytes  in 
antibody production have also been documented in animal 
model (Kennedy et al., 2003).  
In conclusion, immunising HIV/AIDS patients against 
infectious  diseases  will  no  doubt  reduce  morbidity, 
mortality,  and  improve  quality  of  life  in  them.  However, 
because  HIV  infection  alters  immune  functions, 
immunisation in HIV-infected persons may not confer the 
expected  protection  as  in  the  immunocompetent 
individuals and might even worsen their viral status. This 
study has shown that the majority of our cohort of patients 
has  protective  anti-tetanus  antibody  level,  which  is 
probably a reflection of the effectiveness of the National 
Programme on Immunisation in country. 
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